Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare Conference

May 27, 2020 Off By BusinessWire

WALTHAM, Mass.–(BUSINESS WIRE)–Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.

Contacts

Investor Contact:
Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

[email protected]